![Atara Biotherapeutics, Inc. logo](/logos/ATRA.webp)
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Overview | Financials
Company Name | Atara Biotherapeutics, Inc. |
Symbol | ATRA |
Currency | USD |
Price | 9.47 |
Market Cap | 46,545,524 |
Dividend Yield | 0% |
52-week-range | 4.975 - 49 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Pascal Touchon D.V.M. |
Website | https://www.atarabio.com |
An error occurred while fetching data.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD